Entyvio is not a TNF blocker. It belongs to a different class of biologic medications called integrin antagonists. While both Entyvio and TNF blockers treat inflammatory bowel disease (IBD), they work through completely different mechanisms and affect the body in distinct ways.
How Entyvio Actually Works
Entyvio (vedolizumab) targets a specific protein on the surface of immune cells called alpha-4-beta-7 integrin. This protein acts like a homing signal that guides certain white blood cells toward the gut lining. By blocking that signal, Entyvio prevents those immune cells from reaching the intestinal wall, which reduces the inflammation that drives ulcerative colitis and Crohn’s disease.
The key distinction is that Entyvio’s action is gut-selective. It was specifically designed to interrupt immune cell trafficking to the intestines without broadly suppressing the immune system elsewhere in the body. This selectivity is a major reason doctors sometimes choose it over other biologics, particularly for patients concerned about systemic immune suppression.
How TNF Blockers Differ
TNF blockers work by neutralizing tumor necrosis factor-alpha, an inflammatory signaling molecule that circulates throughout the entire body. This makes them systemic drugs. The FDA-approved TNF blockers include Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept), Cimzia (certolizumab pegol), and Simponi (golimumab).
Because TNF-alpha plays a role in inflammation beyond the gut, TNF blockers can also treat conditions like rheumatoid arthritis, psoriasis, and ankylosing spondylitis. That systemic reach is useful for IBD patients who also have inflammation in their joints, skin, or eyes (known as extraintestinal manifestations). Entyvio, because it primarily targets the gut, is less effective for those symptoms outside the digestive tract.
Infection Risk Comparison
Entyvio’s gut-selective design translates into a meaningful safety difference in certain patients. In ulcerative colitis, vedolizumab was associated with a 46% lower risk of serious infections compared to TNF blockers. For Crohn’s disease, the infection rates between the two drug classes were similar, with no statistically significant difference.
This distinction matters because suppressing the immune system always carries infection risk. TNF blockers dampen immune signaling body-wide, which can leave patients more vulnerable to infections in the lungs, skin, and other organs. Entyvio’s more targeted approach appears to spare much of the body’s general immune defense, at least in ulcerative colitis patients.
What Entyvio Treatment Looks Like
Entyvio is approved to treat both ulcerative colitis and Crohn’s disease. Treatment starts with two intravenous infusions: one at the beginning and another two weeks later. Each infusion takes about 30 minutes. At week six, you either continue with IV infusions every eight weeks or switch to a self-administered injection under the skin every two weeks.
If you switch to the subcutaneous form, the dose is smaller (108 mg injected at home versus 300 mg given by IV at a clinic). Patients already responding well to IV therapy can make the switch at any point after week six. If there’s no sign of improvement by week 14, doctors typically discontinue the medication.
Why the Confusion Exists
The mix-up between Entyvio and TNF blockers is understandable. Both are biologic therapies given by infusion or injection, both treat IBD, and both are prescribed by the same specialists. They often come up in the same conversations when a gastroenterologist is deciding which biologic to try first. But they sit in entirely separate drug classes with different targets, different side effect profiles, and different strengths depending on the patient’s specific situation.
For patients with IBD that’s limited to the gut and no significant inflammation elsewhere, Entyvio’s gut-selective approach can be an advantage. For patients dealing with joint pain, skin issues, or eye inflammation alongside their bowel disease, TNF blockers tend to be preferred because their systemic action addresses those problems simultaneously.